Pharmacological targeting of the β-amyloid precursor protein intracellular domain

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Branca, Caterina ^a   Sarnico, Ilenia ^a   Ruotolo, Roberta ^c   Lanzillotta, Annamaria ^a   Viscomi, Arturo Roberto ^c,f   Benarese, Marina ^a   Porrini, Vanessa ^a,b   Lorenzini, Luca ^d   Calzà, Laura ^d   Imbimbo, Bruno Pietro ^e   Ottonello, Simone ^c   Pizzi, Marina ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3',4' DICHLORO 2 FLUORO(1,1' BIPHENYL) 4 YL)CYCLOPROPANECARBOXYLIC ACID; 1-(3',4'-DICHLORO-2-FLUORO(1,1'-BIPHENYL)-4-YL)CYCLOPROPANECARBOXYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; CD82 ANTIGEN; CD82 PROTEIN, HUMAN; CYCLOPROPANE DERIVATIVE; DRUG DERIVATIVE; FLURBIPROFEN; HISTONE; PEPTIDE FRAGMENT; SECRETASE;

ACETYLATION; ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ACETYLATION; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIGENS, CD82; CELL LINE, TUMOR; CYCLOPROPANES; FLURBIPROFEN; HISTONES; HUMANS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION, GENETIC;

EID: 84898459011     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04618     Document Type: Article

References (49)

1. LaFerla, F. M. & Oddo, S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 11, 170-6 (2005).
2. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-66 (2001). (Pubitemid 32267077)
3. Beckett, C., Nalivaeva, N. N., Belyaev, N. D. & Turner, A. J. Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell. Signal. 24, 402-9 (2012).
4. Takami, M. & Funamoto, S. gamma-Secretase-Dependent Proteolysis of Transmembrane Domain of Amyloid Precursor Protein: Successive Tri-and Tetrapeptide Release in Amyloid beta-Protein Production. Int. J. Alzheimers Dis. 2012, 591392 (2012).
5. Zettl, H.,Weggen, S., Schneider, P. & Schneider, G. Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol. Sci. 31, 402-10 (2010).
6. Haapasalo, A. & Kovacs, D. M. The many substrates of presenilin/gammasecretase. J. Alzheimers Dis. 25, 3-28 (2011).
7. Belyaev, N. D. et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a beta-secretase-dependent pathway. J. Biol. Chem. 285, 41443-54 (2010).
8. Goodger, Z. V. et al. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J. Cell Sci. 122, 3703-14 (2009).
9. Ghosal, K. et al. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. U. S. A. 106, 18367-72 (2009).
10. Konietzko, U. AICD nuclear signaling and its possible contribution toAlzheimer's disease. Curr. Alzheimer Res. 9, 200-16 (2012).
11. Buoso, E., Lanni, C., Schettini, G., Govoni, S. & Racchi, M. beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol. Res. 62, 308-17 (2010).
12. Kimberly, W. T., Zheng, J. B., Guenette, S. Y. & Selkoe, D. J. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J. Biol. Chem. 276, 40288-92 (2001).
13. Kinoshita, A.,Whelan, C. M., Smith, C. J., Berezovska, O. & Hyman, B. T. Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J. Neurochem. 82, 839-47 (2002).
14. von Rotz, R. C. et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 117, 4435-48 (2004).
15. Baek, S. H. et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110, 55-67 (2002). (Pubitemid 34874606)
16. Cao, X. & Sudhof, T. C. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-20 (2001). (Pubitemid 32625507)
17. Kim, H. S. et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. Faseb J. 17, 1951-3 (2003).
18. Hebert, S. S. et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 7, 739-45 (2006). (Pubitemid 43986273)
19. Ryan, K. A. & Pimplikar, S. W. Activation of GSK-3 and phosphorylation of CRMP2 in transgenicmice expressing APP intracellular domain. J. Cell Biol. 171, 327-35 (2005). (Pubitemid 41540024)
20. Telese, F. et al. Transcription regulation by the adaptor protein Fe65 and the nucleosome assembly factor SET. EMBO Rep. 6, 77-82 (2005). (Pubitemid 41710078)
21. Ghosal, K., Stathopoulos, A. & Pimplikar, S. W. APP intracellular domain impairs adult neurogenesis in transgenicmice by inducing neuroinflammation. PLoS One 5, e11866 (2010).
22. Passer, B. et al. Generation of an apoptotic intracellular peptide by gammasecretase cleavage of Alzheimer's amyloid beta protein precursor. J. Alzheimers Dis. 2, 289-301 (2000). (Pubitemid 32095613)
23. Muller, T., Meyer, H. E., Egensperger, R. & Marcus, K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 85, 393-406 (2008).
24. Pardossi-Piquard, R. & Checler, F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J. Neurochem. 120 Suppl 1, 109-24 (2012).
25. Imbimbo, B. P. et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982-93 (2009).
26. Lanzillotta, A. et al. The gamma-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 45, 22-31 (2011).
27. Imbimbo, B. P. et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 20, 159-73 (2010).
28. Sivilia, S. et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 14, 44 (2013).
29. Ross, J. et al. CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study. Curr. Alzheimer Res. 10, 742-53 (2013).
30. Imbimbo, B. P. et al. 1-(39,49-Dichloro-2-fluoro[1,19-biphenyl]-4-yl)- cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822-30 (2007). (Pubitemid 350146064)
31. Imbimbo, B. P. et al. Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. Alzheimer Dis. Assoc. Disord. 27, 278-86 (2013).
32. Balducci, C. et al. The gamma-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J. Alzheimers Dis. 24, 799-816 (2011).
33. Giuliani, A. et al. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice. J. Neurochem. 124, 613-20 (2013).
34. Dovey, H. F. et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173-81 (2001). (Pubitemid 32044380)
35. Kukar, T. L. et al. Substrate-targeting gamma-secretase modulators. Nature 453, 925-9 (2008).
36. Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A. & Miele, L. gamma-Secretase inhibitors and modulators. Biochim. Biophys. Acta (2013).
37. Takami, M. et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042-52 (2009).
38. Kinoshita, A., Whelan, C. M., Berezovska, O. & Hyman, B. T. The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277, 28530-6 (2002). (Pubitemid 41079279)
39. Cao, X. & Sudhof, T. C. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279, 24601-11 (2004). (Pubitemid 38725327)
40. Barbagallo, A. P. et al. Tyr(682) in the intracellular domain of APP regulates amyloidogenic APP processing in vivo. PLoS One 5, e15503 (2010).
41. Xie, Z., Dong, Y.,Maeda, U., Xia, W. & Tanzi, R. E. RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation. J. Biol. Chem. 282, 4318-25 (2007). (Pubitemid 47100999)
42. Galvan, V. et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. U. S. A. 103, 7130-5 (2006).
43. Lichtenstein, M. P. et al. Secretase-independent and RhoGTPase/PAK/ ERKdependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives. J. Alzheimers Dis. 22, 1135-55 (2010).
44. Muller, T. et al. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol. Biol. Cell 18, 201-10 (2007). (Pubitemid 46066721)
45. Ma,H. et al. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 104, 8167-72 (2007).
46. Belyaev, N. D., Nalivaeva, N. N., Makova, N. Z. & Turner, A. J. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 10, 94-100 (2009).
47. Pimplikar, S. W. & Suryanarayana, A. Detection of APP intracellular domain in brain tissue. Methods Mol. Biol. 670, 85-91 (2011).
48. Winkler, E. et al. Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry 48, 1183-97 (2009).
49. Rubio, I. et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 27, 1949-56 (2009).